New York, NY, Apr 04: A groundbreaking collaborative study co-led by scientists at the Icahn School of Medicine at Mount Sinai and the Lieber Institute for Brain Development has, for the first time, identified a critical biological mechanism that may explain how brain development differs in individuals with Down syndrome.
The research, published in Nature Communications on March 31, reveals that an overactive gene called ADARB1 (also known as ADAR2) plays a central role in altering early brain development. The study was conducted in collaboration with the Medical University of Sofia in Bulgaria and the University of Arizona.
Down syndrome, also known as trisomy 21, occurs when an individual has an extra copy of chromosome 21—where the ADARB1 gene is located. While this genetic condition has long been associated with developmental differences, the precise biological mechanisms affecting early brain formation have remained unclear—until now.
“Our findings help explain how an extra copy of chromosome 21 reshapes the brain from the earliest stages of development,” said Michael S. Breen, PhD, Associate Professor at Mount Sinai. “We discovered that increased levels of the ADARB1 enzyme lead to earlier and more extensive RNA editing in developing neurons, which may influence how brain circuits are formed from the very beginning.”
Key Findings:
- Elevated levels of the ADARB1 enzyme in trisomy 21 brains lead to excessive RNA editing
- RNA messages are altered prematurely, impacting how neurons communicate
- Critical brain regions such as the prefrontal cortex and hippocampus show disrupted development
- Key neuronal genes involved in signaling—such as GRIA2, GRIA3, GRIK2, and GABRA3—are significantly affected
The research team analyzed brain tissue samples collected between 13 and 22 weeks of gestation, a crucial window for early brain development. Using advanced RNA sequencing techniques, they identified widespread disruption in gene expression and RNA editing patterns in individuals with trisomy 21.
To validate their findings, researchers conducted a combined analysis of nine independent datasets, all of which confirmed the same pattern: increased ADARB1 activity and elevated RNA editing linked to the extra chromosome.
“These findings redefine our understanding of Down syndrome neuropathology,” said Joseph D. Buxbaum, PhD, Professor at Mount Sinai. “They establish RNA editing as both a measurable biomarker of early brain development and a promising target for future therapeutic interventions.”
The study highlights ADARB1-driven RNA editing dysregulation as a fundamental molecular consequence of chromosome 21 triplication, directly linking genetic imbalance to altered neuronal signaling.
Researchers believe these insights could pave the way for new diagnostic tools and precision therapies aimed at improving neurological and behavioral outcomes in individuals with Down syndrome.
